On July 14, 2020 Celsion Corporation (NASDAQ: CLSN) reported that it will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its current observations about the results of the OPTIMA Study and the Company’s next steps (Press release, Celsion, JUL 14, 2020, View Source [SID1234561858]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, interested parties may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978 (International/Toll) 10 minutes before the call is scheduled to begin using the Conference ID 1879551. The conference call will be webcast via the Investors page on the Company’s website at View Source The call will be archived for replay through July 29, 2020. The replay can be accessed at 1-719-457-0820 or 1-888-203-1112 using Conference ID 1879551. Approximately two hours following the live event, an audio replay of the conference call will also be available on the Company’s website for 90 days.

On July 14, 2020 Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, reported it has appointed Christopher Slapak, MD, as Chief Medical Officer (Press release, Vor BioPharma, JUL 14, 2020, View Source [SID1234561856]). Dr. Slapak has more than 20 years of leadership experience in oncology drug development and previously led global clinical development for all early-stage oncology compounds for Eli Lilly and Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As Vor rapidly advances to become a clinical-stage company, it is wonderful for Christopher to commit to this full-time role leading the development of our oncology therapeutics," said Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer.

Dr. Slapak has served as Vor’s Interim Chief Medical Officer since July 2019 as part of his work as an independent consultant advising on scientific and medical aspects of oncology drug development. For more than 20 years, he held leadership roles at Eli Lilly and Company, including positions as Distinguished Lilly Scholar and Vice President, Early Phase Research. He oversaw the global clinical development of all early-stage oncology compounds for Lilly and ImClone (which was acquired by Lilly in 2008), including the successful early-stage development of abemaciclib (Verzenio).

Dr. Slapak received his medical degree from the University of Chicago Pritzker School of Medicine, where he also completed his residency in internal medicine. After fellowship training in hematology and oncology at Tufts/New England Medical Center, Dr. Slapak was appointed Instructor and then Assistant Professor of Medicine at the Dana-Farber Cancer Institute/Harvard Medical School. He is board certified in internal medicine, medical oncology and hematology and currently has a joint appointment as Clinical Associate Professor of Medicine and Pharmacology at the Indiana University School of Medicine.

"Vor’s approach to engineering hematopoietic stem cells that are invulnerable to targeted therapies is a major innovation in stem cell transplantation," Dr. Slapak said. "Acute myeloid leukemia, a cancer of the bone marrow and our lead indication, constitutes a major unmet medical need – more than 20,000 people in the U.S. are diagnosed annually and less than 30% survive five years after diagnosis. By rendering healthy blood and bone marrow cells invisible to CD33-targeted therapies, we hope to provide long-term remissions for these patients, ultimately improving and prolonging life."

On July 14, 2020 Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, reported the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 2,100,000 additional shares of common stock, at a public offering price of $18.00 per share (Press release, Nkarta, JUL 14, 2020, View Source [SID1234561855]). The aggregate gross proceeds from the offering were $289.8 million, before deducting underwriting discounts and commissions and other offering expenses payable by Nkarta. All shares in the offering were offered by Nkarta. Nkarta’s common stock began trading on The Nasdaq Global Select Market on July 10, 2020 under the ticker symbol "NKTX."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen, Evercore ISI, Stifel and Mizuho Securities acted as joint book-running managers for the offering.

A registration statement relating to these securities was filed with the Securities and Exchange Commission and became effective on July 9, 2020. The offering was made only by means of a prospectus, copies of which may be obtained from Cowen and Company, LLC, Attn: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at [email protected], or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by telephone at 888-474-0200, or by email at [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at (415) 364-2720 or by email at [email protected]; Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, or by email at [email protected], or by telephone at (212) 205-7600.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On July 14, 2020 ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, reported that it hosted a virtual Analyst Day event on Tuesday, July 7th, 2020 (Press release, ImmunSYS, JUL 14, 2020, View Source;utm_medium=rss&utm_campaign=immunsys-announces-it-hosted-a-virtual-analyst-day-event-on-july-7-2020 [SID1234561854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eamonn Hobbs, Chairman and CEO of ImmunSYS and Charles J. Link, Jr., M.D., Chief Medical Officer and President of ImmunSYS provided a business overview and highlighted upcoming milestones. Two world-renowned, key opinion leaders, E. David Crawford, M.D. Professor of Urology at the University of San Diego, and Steven J. O’Day, M.D., Executive Director of the John Wayne Cancer Institute and Cancer Clinic provided updates on the current prostate cancer landscape and reviewed new data on the company’s platform technology, YourVaccx. Dr. O’Day provided an in-depth review of the company’s Proof of Concept (PoC) study data that was recently presented at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting II.

A replay of the event can be accessed on the ImmunSYS website in the ‘Publications’ section at www.immunsys.com/publications

On July 14, 2020 Sanofi and The University of Texas MD Anderson Cancer Center reported a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune-therapies, for patients with cancer (Press release, Sanofi, JUL 14, 2020, View Source [SID1234561852]). The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our goal is to improve the outcome for patients with a range of difficult-to-treat cancers, which is best achieved through a deep understanding of how investigational new drugs work," said Peter Adamson, M.D., Global Development Head, Oncology and Pediatric Innovation at Sanofi. "This alliance leverages MD Anderson’s agile approach to early phase clinical trials, their laboratory capabilities and broad scientific expertise. This will get us to go/no-go decisions much faster and help us identify potential new combinations and indications more accurately. That will save precious time and help us expand the spectrum of patients who could potentially benefit from our therapies."

MD Anderson manages one of the country’s largest oncology clinical trial programs, with well-established platforms for tissue collection, molecular and immune profiling, and data analysis. This infrastructure enables the comprehensive study of tumor samples taken before, during and after treatment to uncover valuable insights that help streamline patient selection and hasten the identification of new therapy combinations and indications.

"Not only do clinical trials help us to advance life-saving new treatments for our patients in need, they provide us with valuable information to understand which therapies may be more effective for which patients," said Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics. "We are pleased to collaborate with Sanofi in this effort to accelerate the development of a pipeline of innovative cancer therapies."

The new alliance also will support investigations into additional indications and combinations for studies already in the clinic. Sanofi and MD Anderson scientists will collaborate on experimental design, applying a core set of biomarkers and assays. Joint projects also will apply novel investigational agents developed at Sanofi to existing tumor samples to obtain further data on their effects at different disease stages.

"MD Anderson’s expertise in deep immune phenotyping and molecular profiling will provide invaluable insights into our emerging immunotherapy assets, helping us refine our selection of indications and explore new avenues," said Dmitri Wiederschain, Ph.D., Global Head of Immuno-Oncology Research at Sanofi. "The knowledge we gain in this collaboration will also deepen our shared understanding of cancers’ potential vulnerabilities."

New findings, as well as large-scale molecular and phenotype datasets, will be applied to the design of new translational studies on selected Sanofi molecules, and guide the selection of indications. The collaboration is expected to launch its first projects in summer 2020.